Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry man. Good luck with your trade. PCLN is a good one if you bet it right.
Agree. Fast way to buy that box to live in at the beach
Damn 30K for a weekly. Vegas baby.
so true. Looking at SBUX puts for nov 19th. Looking good and it seems that coffee stocks are somewhat symbiotic i might get in since GMCR, and tim hortons fins are due this week.
thanx. I was going to hold and could of made more but I have Gordon Geckos ethos ringing in my brain. Bulls make money, bears make money. Pigs get slaughtered.
Mornin. Sold STX call. Got in at .02 sold at .21
option to not buy CURX.
gap and trap.
CURX is not the cure. Sorry.
CURX and unregistered shares to be sold.
The stock sale to southridge is to be unregistered. Thats right unregistered so they can hit the market as fast as CURX draws down their credit limit. Almost 13m shares at .35. So if the stock price is at .06 Southridge gets to dump more shares to make up the difference.
What doers this mean. It means to the investor that dumping will continue for the forseeable future.
We are relying on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 of Regulation D promulgated thereunder. The transaction does involve a private offering, Southridge is an “accredited investor” and/or qualified institutional buyer and Southridge has access to information about our Company and its investment
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8105485
Do you have proof that hedge funds are buying CURX? If not then false and misleading info is against sec rules for stock manipulation.
CURX and its lawsuits.
CURX has over 1.7M dollars in lawsuits and pending lawsuits.
These lawsuits were as a result of the failed clinical trials in 2007. the people owed are very important in the Alzheimers arena and CURX has failed to satisfy their debt with them. legal fees are at 105K to deal with litigation.
In 2008, Aptuit, Inc. obtained a judgment for approximately $1.1M in the Circuit Court of Jackson County, Missouri at Kansas City, relating to work it performed for Curaxis in connection with our truncated ALADDIN 301 trial. Aptuit’s claims were based on invoices previously rendered to Curaxis in connection with that work and on a promissory note that Curaxis had delivered to Aptuit in connection with those invoices. We subsequently entered into a settlement agreement with Aptuit that requires payment of $900,000 over the next two years to satisfy this judgment. To date, Curaxis has made payments totaling $400 thousand under the terms of the agreement.
In 2009, Genzyme Corporation obtained a judgment for $424,000 in the United States District Court for the District of Massachusetts, relating to leuprolide supplied to Curaxis in 2006 for our truncated ALADDIN 301 trial. Curaxis did not oppose the entry of this judgment, as it had previously acknowledged the validity of this debt to Genzyme. Genzyme had informally agreed through their counsel to defer any collection activities until approximately early 2011. On May 13, 2011, the Company was served with a First Execution Notice demanding payment of the identified liabilities; a deposition was also scheduled for July 10, 2011. Due to the significant changes in the Company’s management team effective June 24, 2011, Genzyme has informally agreed to delay the proceedings. We expect to have discussions with Genzyme to establish a payment schedule for this judgment during the third quarter of 2011.
In 2009, Margolin Brain Institute obtained a default judgment for $128,469, including interest and attorneys fees, in the Superior Court of the State of California, Fresno County - Civil Division, relating to work it performed in our truncated ALADDIN 301 trial. We expect to engage in discussions concerning settlement and payment of this judgment later in 2011.
The increase in general and administrative expenses for the three months ended June 30, 2011, as compared to the same period for 2010, is primarily related an increase in legal fees. Legal fees for the three months ended June 30, 2011, totaled $105 thousand compared to $49 thousand for the corresponding period of 2010; an increase of $56 thousand
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721
Sorry but this is CURX. Again do you have proof?
Do you have proof of hedge fund boys coming in? Please do not post false rumors to manipulate the price of a stock.
Just wait in 10 minutes the real deal behind CURX
Lawsuits and debt coming up.
Here is the 4.3M deal you speak of.
At the assumed offering price of $0.35 per share, we will be able to receive up to $4,304,145 in gross proceeds, assuming the sale of the entire 12,297,557 shares of our common stock being registered hereunder pursuant to the Equity Credit Agreement. We would be required to register additional shares to obtain the balance of $25,000,000 under the Equity Credit Agreement if the market price of the stock remains stable or falls below the assumed offering price of $0.35. Neither the Equity Credit Agreement nor any rights or obligations of the parties under the Equity Credit Agreement may be assigned by either party to any other person.
There are substantial risks to investors as a result of the issuance of shares of our common stock under the Equity Credit Agreement. These risks include dilution of stockholders, significant decline in our stock price and our inability to draw sufficient funds when needed.
Southridge will periodically purchase our common stock under the Equity Credit Agreement and will, in turn, sell such shares to investors in the market at the market price. This may cause our stock price to decline, which will require us to issue increasing numbers of common shares to Southridge to raise the same amount of funds, as our stock price declines.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8105485
Here is the real story behind the curtain.
DUE TO A LACK OF FINANCIAL RESOURCES, WE HAVE BEEN UNABLE TO ADVANCE THE CLINICAL DEVELOPMENT OF OUR LEAD PRODUCT CANDIDATE SINCE 2006.
Our lead product candidate is a hormone for the treatment of Alzheimer’s disease. We have previously conducted several clinical trials for this indication, the most recent of which we were forced to terminate in 2006 due to financial constraints. Since terminating those trials, we have been unable to advance the clinical development of our Alzheimer’s disease candidate due to a lack of financial resources. We anticipate that we will be able to raise the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, but there can be no assurance that we will be able to do so. Furthermore, even if we are successful in raising the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, there can be no assurance that we will be able to successfully complete all phases of such clinical development. Drug development is extremely costly and complex and requires multiple clinical trials and we may be unable to obtain suitable financing for all such trials and, even if we are successful in obtaining suitable financing, we may be unable to complete all required clinical trials due to an inability to recruit an adequate number of clinical trial sites or an adequate number of patients to participate in those trials or other reasons.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8105485
Yes gagged. It was the T/A gagging the share structure and only the CFO can give out the info.
So please lets say 9it together. gagged.
Thanks. Confirmed what I have been saying. Gagged. If a CFO is the only person to put out the float it means they gagged the T/A from giving out the info.
I do believe it could ripple down to other groups and brokerages if the U.S decides to invoke the full power of the Volcker rule.
Yea I remember last week when it was rumored that the greek PM would quit that day, But it turned out to be fact a couple of days later.
Mornin U-P-B. I guess we get to see the CME make huge margin calls today.
I am loving WDC hitting highs. Will make the crash that much sweeter. LOL
Another European PM bites the dust.
Italian Prime Minister Silvio Berlusconi said to step down today.
http://www.bloomberg.com/news/2011-11-07/european-stock-index-futures-decline-ryanair-ubs-shares-may-be-active.html
Truth behind CURX memryte. Nothing since 2006. The only thing CURX has going for it is a huge awareness campaign that cost investors thousands.
DUE TO A LACK OF FINANCIAL RESOURCES, WE HAVE BEEN UNABLE TO ADVANCE THE CLINICAL DEVELOPMENT OF OUR LEAD PRODUCT CANDIDATE SINCE 2006.
Our lead product candidate is a hormone for the treatment of Alzheimer’s disease. We have previously conducted several clinical trials for this indication, the most recent of which we were forced to terminate in 2006 due to financial constraints. Since terminating those trials, we have been unable to advance the clinical development of our Alzheimer’s disease candidate due to a lack of financial resources. We anticipate that we will be able to raise the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, but there can be no assurance that we will be able to do so. Furthermore, even if we are successful in raising the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, there can be no assurance that we will be able to successfully complete all phases of such clinical development. Drug development is extremely costly and complex and requires multiple clinical trials and we may be unable to obtain suitable financing for all such trials and, even if we are successful in obtaining suitable financing, we may be unable to complete all required clinical trials due to an inability to recruit an adequate number of clinical trial sites or an adequate number of patients to participate in those trials or other reasons.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8105485
Sadly Mr. Smith is no longer with CURX. That statement is general in nature and does not say anything about CURX nor does CURX have any drug in the pipeline.
Do you know what that means oligomenohrrea and secondary amenorrhea. They say it is better to say what you understand than to write what you do not. LOL
the 4.3m truth.
At the assumed offering price of $0.35 per share, we will be able to receive up to $4,304,145 in gross proceeds, assuming the sale of the entire 12,297,557 shares of our common stock being registered hereunder pursuant to the Equity Credit Agreement. We would be required to register additional shares to obtain the balance of $25,000,000 under the Equity Credit Agreement if the market price of the stock remains stable or falls below the assumed offering price of $0.35. Neither the Equity Credit Agreement nor any rights or obligations of the parties under the Equity Credit Agreement may be assigned by either party to any other person.
There are substantial risks to investors as a result of the issuance of shares of our common stock under the Equity Credit Agreement. These risks include dilution of stockholders, significant decline in our stock price and our inability to draw sufficient funds when needed.
Southridge will periodically purchase our common stock under the Equity Credit Agreement and will, in turn, sell such shares to investors in the market at the market price. This may cause our stock price to decline, which will require us to issue increasing numbers of common shares to Southridge to raise the same amount of funds, as our stock price declines.
The truth behind the 4.3M stock buying.
At the assumed offering price of $0.35 per share, we will be able to receive up to $4,304,145 in gross proceeds, assuming the sale of the entire 12,297,557 shares of our common stock being registered hereunder pursuant to the Equity Credit Agreement. We would be required to register additional shares to obtain the balance of $25,000,000 under the Equity Credit Agreement if the market price of the stock remains stable or falls below the assumed offering price of $0.35. Neither the Equity Credit Agreement nor any rights or obligations of the parties under the Equity Credit Agreement may be assigned by either party to any other person.
There are substantial risks to investors as a result of the issuance of shares of our common stock under the Equity Credit Agreement. These risks include dilution of stockholders, significant decline in our stock price and our inability to draw sufficient funds when needed.
Southridge will periodically purchase our common stock under the Equity Credit Agreement and will, in turn, sell such shares to investors in the market at the market price. This may cause our stock price to decline, which will require us to issue increasing numbers of common shares to Southridge to raise the same amount of funds, as our stock price declines.
Calling Dec puts on western Digital (WDC).
Western Digital to miss estimates in December due to both factories in thailand inundated still with over 1.5m of water. It looks like those factories will not be fully operational until sometime next year.
Western Digital HDD output from thailand is 60%.
Truth behind CURX memryte. Nothing since 2006. The only thing CURX has going for it is a huge awareness campaign that cost investors thousands.
DUE TO A LACK OF FINANCIAL RESOURCES, WE HAVE BEEN UNABLE TO ADVANCE THE CLINICAL DEVELOPMENT OF OUR LEAD PRODUCT CANDIDATE SINCE 2006.
Our lead product candidate is a hormone for the treatment of Alzheimer’s disease. We have previously conducted several clinical trials for this indication, the most recent of which we were forced to terminate in 2006 due to financial constraints. Since terminating those trials, we have been unable to advance the clinical development of our Alzheimer’s disease candidate due to a lack of financial resources. We anticipate that we will be able to raise the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, but there can be no assurance that we will be able to do so. Furthermore, even if we are successful in raising the funds necessary to restart the clinical development of our Alzheimer’s disease candidate, there can be no assurance that we will be able to successfully complete all phases of such clinical development. Drug development is extremely costly and complex and requires multiple clinical trials and we may be unable to obtain suitable financing for all such trials and, even if we are successful in obtaining suitable financing, we may be unable to complete all required clinical trials due to an inability to recruit an adequate number of clinical trial sites or an adequate number of patients to participate in those trials or other reasons.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8105485
never do. LOL.
These so called partners were in 2007 and earlier. Some of the links are not found and if you go to DURECT website you will see the last update about memryte is 2007.
Do you have any recent real partners?
• Our collaboration in discovery research with leading Alzheimer's research
teams led by George Perry, PhD, Mark A. Smith, PhD (
http://www.cwru.edu/med/pathology);
• Leading patent and FDA legal support from Covington & Burling (
http://www.cov.com);
• Clinical and FDA regulatory support from Bert Spilker & Associates (
http://www.bertspilker.com);
• Drug development and delivery support from DURECT Corporation (
http://www.durect.com);
• Website and marketing communications support by Sage Communications, LLC.
(http://www.aboutsage.com)
No real science to back that up. No one has furthered the science since it was shut down in 2007.
No scientific proof of that. If there was, then major drug companies would of bought them out, or they would of found financing after 2007. Sadly they did not.
In June 2011 CURX was over 90m in debt and looking at 4.3M in toxic financing and another 12M in Put options on their own company.
The address is Mrs. Gleason home address.LOL
The company's lease on office space in Durham expired in February. Curaxis then moved its official headquarters to a small space in Swampscott, Mass., which was provided rent-free by Corcoran, according to its SEC filing.
Mrs.Geaslen, who works out of her Raleigh home, said it is too soon to say whether the company will again expand in the Triangle
Read more: http://www.newsobserver.com/2011/06/28/1306160/curaxis-overhauls-its-top-leadership.html#ixzz1d0M0jfZX
About Patrick Smith.
Mr. Smith who founded Voyager pharm back in the 1990's decided to look at a cure for alzheimers. In 2001 he received financial backing from investors and over the years totaled over 60M dollars.
The drug is called Memryte. DURECT a bio tech firm that helps startup companies, worked with Voyager until 2007 when memryte was seen to be ineffective against Alzheimers. Voyager countered back with the story that it works in women. DURECT did not believe the data and pulled out. In 2007 CURX closed its doors.
In 2005 Mr. Smith tried to go the IPO route but did not get enough backers so decided to forego the IPO route.
in 2010 Mr. Smith bought a shell from Autosearch cars. Since 2010, CURX has lost their space in North carolina, Mrs. GLeason works from home,and the company had to take a small space in massachusetts from Mr. Corcoran. no revenue, no drug, no share value.
On Jun 24th 2011 Mr. Smith and four other board members walked out.
CURX with major litigation problems.
The total value of litigation is over 1.7m dollars. When their drug Memryte was shut down in 2007 CURX stopped paying the bills to those who helped with the study. here is a list of suits pending and/or judgement given.
In 2008, Aptuit, Inc. obtained a judgment for approximately $1.1M in the Circuit Court of Jackson County, Missouri at Kansas City, relating to work it performed for Curaxis in connection with our truncated ALADDIN 301 trial. Aptuit’s claims were based on invoices previously rendered to Curaxis in connection with that work and on a promissory note that Curaxis had delivered to Aptuit in connection with those invoices. We subsequently entered into a settlement agreement with Aptuit that requires payment of $900,000 over the next two years to satisfy this judgment. To date, Curaxis has made payments totaling $400 thousand under the terms of the agreement.
In 2009, Genzyme Corporation obtained a judgment for $424,000 in the United States District Court for the District of Massachusetts, relating to leuprolide supplied to Curaxis in 2006 for our truncated ALADDIN 301 trial. Curaxis did not oppose the entry of this judgment, as it had previously acknowledged the validity of this debt to Genzyme. Genzyme had informally agreed through their counsel to defer any collection activities until approximately early 2011. On May 13, 2011, the Company was served with a First Execution Notice demanding payment of the identified liabilities; a deposition was also scheduled for July 10, 2011. Due to the significant changes in the Company’s management team effective June 24, 2011, Genzyme has informally agreed to delay the proceedings. We expect to have discussions with Genzyme to establish a payment schedule for this judgment during the third quarter of 2011.
In 2009, Margolin Brain Institute obtained a default judgment for $128,469, including interest and attorneys fees, in the Superior Court of the State of California, Fresno County - Civil Division, relating to work it performed in our truncated ALADDIN 301 trial. We expect to engage in discussions concerning settlement and payment of this judgment later in 2011.